Despite extensive research carried out over many years, a completely satisfactory method of testing drugs and chemicals for carcinogenicity continues to elude toxicologists. In the past, numerous scientific groups, regulatory agencies, and regional bodies have discussed and published specific recommendations and guidelines regarding the testing requirements for carcinogenicity studies. The Food, Drug and Cosmetic Act became law in 1938, but it was not until after the Second World War that serious concerns regarding chemicals became prevalent. Testing guidelines were nonexistent until 1949 when the FDA published "Procedures for the Appraisal of the Toxicity of Chemicals in Foods." This key publication was the forerunner of the famous "Gray Book" (1959) in which were outlined many of the specific carcinogenicity testing procedures still used today. Guidelines and regulations became the watchwords during the 60's and 1970's. Formation of the EPA, more stringent testing requirements, Toxic Substances legislation, and Environmental Control Acts followed one another in short order. NCl's Technical Report #1 (1976) entitled, "Guidelines for Carcinogen Bioassay in Small Rodents" probably had the greatest impact of any publication on carcinogenicity testing. Many later guidelines and recommendations were based on this publication.
The purpose of performing toxicology studies is to evaluate the probability that a chemical entity, or its metabolite, will not produce significant adverse effects under specified conditions of use. Carcinogenicity bioassays are not separate entities but only special types of toxicity studies. Their raison d'etre is to predict that tumors, of whatever nature, will not be produced in animals and/or humans exposed to reasonable-use concentrations of the compound in question. Yet, all too frequently this simple objective cannot be achieved, and despite extensive research carried out over many years, a completely satisfactory method of testing drugs and *Presented at the Second International Symposium of the Society of Toxicologic Pathologists, Session I: "Protocols Past and Present", May 9-11, 1983, Arlington, Virginia. This Symposium section will be continued in Volume 11. Number 2, 1983. chemicals for carcinogenicity continues to elude the scientist.
Ever since Sir Percivall Pott demonstrated that the scrota1 neoplasms of chimney sweeps were produced by soot (later identified as aromatic hydrocarbons), scientists have known that chemicals could produce cancer. However, it was not till after the Second World War that serious concerns regarding the testing of chemicals became prevalent. One must remember that chemicals in those days were not as prevalent as today; the Food, Drug and Cosmetic Act did not cbme into being until 1938; and there were relatively few toxicologists in the period of 1938-1955. Toxicology during this particular era was an art form and there were few regulations and no guidelines. However, there were some key publications which outlined the state of the art during the 1940's. Among these publications, the FDA "Procedures for the Ap-38 DIENER praisal of the Toxicity of Chemicals in Foods" was considered the Bible. It was first published in 1949 and then revised in 1955. In 1959, the FDA published its now famous "Gray Book" which was officially known as "Appraisal of the Safety of Chemicals in Foods, Drugs, and Cosmetics." In this publication respected government toxicologists and pharmacologists such as Arnold Lehman, 0. G. Fitzhugh, and Arthur Nelson outlined the general testing procedures which we still follow today. For instance, the concept of using rats for chronic toxicity studies for a period of 2 years was mentioned by Dr. Fitzhugh when he wrote ". . . it is advisable to sacrifice all remaining animals at some arbitrary time, such as 2 years." Contrary to what some people think, two-year studies are no recent innovation. Between 1941 and 1948 Dr. Fitzhugh published results of about 14,2year rodent studies which included such substances as cadmium, selenium, ergot, DDT, and sulfites.
Specific carcinogenicity guidelines were outlined in the "Gray Book" by Bob Zwickey, who was then a member of the FDA's Pathology Branch. Some of the points which he made in his article are still germaine today and include:
Use of mice and rats for carcinogenicity tests. Use of high but nontoxic doses. Recording of gross "lumps & bumps." Observation of latency period for tumor Difficulty in separating benign and ma-Use of 50 rats/group/sex.
Recognition of dietary factors in tumor
The following quotation from Dr. Zwickey is also particularly pertinent whenever we attempt to over-extrapolate or over-manipulate available test data:
"When completed, animal experiments can be interpreted to mean only that the test substance will (or will not) produce tumors in the particular strain of animals used when administered by the specified route within the time allowed in the test."
The pathology discussion, written by Arthur Nelson, Chief of the FDA Pathology Branch, also is surprisingly current with modern concepts. Some of these concepts were not emphasized again until the promulgation of Good Laboratory Practices in 1978. formation. lignant tumors.
formation.
TOXICOLOGIC PATHOLOGY
Use of pathologists in the planning of toxicology experiments. Use of the same pathologist for gross and microscopic examination. Gross lesions should be described and measured. Histopathology should be done on animals which die on test. Microscopic lesions should be described adequately and graded. As statkd priviousiy, the FDA publications of the 1940's and 1950's disseminated the state of the art, but definite and specific requirements were still in the future. Many drugs and chemicals were marketed which had only minimal toxicity characterization and certainly no carcinogenicity evaluations. During the 1960's however, things began to change. Increases in the number of published toxicology reports, conferences, and symposia, as well as press reports of spectacular mishaps such as the "cranberry crisis," the thalidomide episode, and fish and bird kills, provoked government and industry action. As a result, long-term carcinogenicity studies in rodents, along with many other tests, were advocated to safeguard man and his environment.
Guidelines and regulations became the watchwords during the late 60's and the 1970's (see Table I ). Formation of the EPA, more stringent IND and NDA requirements, toxic substances legislation and environmental control acts followed one another in short order. In 1968, FDA published guidelines in the "FDA Papers" which are still being used today for determining the length of clinical trials based on existing animal data. These guidelines were later revised and updated by Dr. D'Aguanno of the FDA. Next came guidelines proposed by a joint FDA-PMA working committee. These guidelines were disseminated to PMA members and FDA in 1974 and served to establish minimum standards of testing. Some of the guidelines were revised in 1980.
The NCI Technical Report #1 of February, 1976, entitled "Guidelines for Carcinogen Bioassay in Small Rodents" probably had the greatest impact on carcinogenicity testing during this time period. Some of the requirements and recommendations that were mentioned were the following:
Bioassays in two species. No strains were advocated. Minimum of 50 animals/group/sex. Periodic analysis of diets for contaminants such as estrogens, aflatoxins, and pesticides. Periodic analysis of diets to verify concentrations of active ingredient. Pathology processing recommendations (fixing time, specimen size, section thickness). Animal husbandry recommendations (cage type and size, bedding, cleaning procedures). Worker safety recommendations (protective clothing, handling of chemicals). Statistical procedures recommendations. Many of the laier guidelines and recommendations such as those from the EPA and OECD were based on this comprehensive publication.
Where do we stand today with all these guidelines and regulations? Unfortunately, they are all still with us and one unified set of guidelines has not entirely replaced the many, although that was the hope when In-Jeragency Regulatory Liaison Group (IRLG) guidelines were initiated. These IRLG guidelines were very similar to the Organization for Economic Cooperation and Development (OECD) guidelines. However, complete unanimity or acceptance has not occurred on all items or with all agencies. Whether complete agreement will ever occur is not known but it appears unlikely. Meanwhile, the toxicologist or pathologist is stuck as to which guidelines to follow, especially when a submission has to be made to more than one agency or country. The mere fact that we are here at this meeting indicates that many problems still exist and that the ultimate protocol is yet to be developed.
From an overview or "birdseye" view, carcinogenicity bioassays still have many problems which continually manifest themselves.
A few examples of major problems are listed below. Later speakers will elaborate on many of these items.
1.
2.

3.
Extrapolation of data from one species to another or from animals to man continues to be a hazardous undertaking. Even with the aid of in-vitro short-term tests, risk assessment leaves much to be desired. In a review conducted by Haberman for instance, 17 actual or suspected human tumorigenic agents were adequately tested in the NCI Bioassay Program. Fourteen agents tested in rats had a common tumor site with humans while only eight tested in mice had a common site with humans. One agent was negative in mice (see Table 11 ). Statistical interpretation of bioassay results are often too sensitive and do not realistically assess the crude nature of the test system. A detailed analysis has recently been published by Salsburg on this subject. More emphasis should be placed on dose relationships and the overwhelming of natural physiological mechanisms than on p values or Fisher's Exact Test. The p value should not be used solely in making qualitative judgments about carcinogenicity. The relative importance of malignant tumors versus benign tumors versus hyperplasia must be better defined. The inability to interpret mouse liver lesions or rat adrenal gland hyperplasia illustrates the problem. Pathologists must adequately define terminology so that Can other short-cuts be taken to decrease costs and possibly also increase predictability? These and many more questions will be addressed by following speakers and hopefully some novel ideas and programs will result from the discussions.
